PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32541643-12	2020	CONCLUSIONS Valsartan inhibited the increase in hs-CRP and IL-6 levels, improved clinical efficacies, increased ABI, and decreased the restenosis rate after the interventional therapy in patients with arteriosclerosis obliterans of the lower extremities.	Valsartan	12-21	C-reactive protein	Homo sapiens	51-54	
32923098-0	2020	C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients.	Valsartan	45-54	C-reactive protein	Homo sapiens	0-18	
32923098-10	2020	After 6 months of Sacubitril-Valsartan therapy, 24 (69%) patients had an improvement in CRP values with a significantly reduction as compared to baseline (median 2.5 mg/L (Interquartile range (IQR) 1.3-5.0) vs. 2.2 mg/L (IQR 0.9-4.0), P=0.014 in the Wilcoxon test).	Valsartan	29-38	C-reactive protein	Homo sapiens	88-91	
32923098-12	2020	CONCLUSION: Sacubitril/Valsartan therapy was able to reduce CRP values in a chronic HF population.	Valsartan	23-32	C-reactive protein	Homo sapiens	60-63	
19911855-9	2009	Consistent with its angiotensin receptor-blocking effects, valsartan also reduces circulating levels of biochemical markers that are associated with angiotensin II-mediated endothelial dysfunction and CV risk (e.g. high-sensitivity C-reactive protein or oxidized low-density lipoprotein).	Valsartan	59-68	C-reactive protein	Homo sapiens	232-250	
20664555-9	2011	A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group.	Valsartan	118-127	C-reactive protein	Homo sapiens	77-95	
20664555-9	2011	A positive correlation between the reduction in OPN and the log natural (ln) C-reactive protein (CRP) was seen in the valsartan-treated group.	Valsartan	118-127	C-reactive protein	Homo sapiens	97-100	
23148500-2	2013	We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension.	Valsartan	39-48	C-reactive protein	Homo sapiens	80-98	
23148500-2	2013	We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension.	Valsartan	39-48	C-reactive protein	Homo sapiens	100-103	
17923463-1	2008	BACKGROUND: The Val-MARC trial showed that the angiotensin receptor blocker valsartan reduces high-sensitivity C reactive protein (hsCRP) levels, an effect that is independent of blood pressure, and seems to be neutralised by the addition of hydrochlorothiazide.	Valsartan	76-85	C-reactive protein	Homo sapiens	111-129	
16939632-6	2006	Angiotensin receptor blockers (ARBs) (valsartan, irbesartan, olmesartan, telmisartan) markedly reduce serum levels of CRP.	Valsartan	38-47	C-reactive protein	Homo sapiens	118-121	
16129801-0	2005	C-reactive protein in heart failure: prognostic value and the effect of valsartan.	Valsartan	72-81	C-reactive protein	Homo sapiens	0-18	
16129801-2	2005	We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan.	Valsartan	160-169	C-reactive protein	Homo sapiens	130-133	
16129801-5	2005	Interactions were tested to determine whether differences in CRP changes from baseline to 4 and 12 months between groups randomly assigned to valsartan or placebo depended on baseline ACE inhibitor use.	Valsartan	142-151	C-reactive protein	Homo sapiens	61-64	
16129801-11	2005	CRP did not change significantly over time in the placebo group; however, after 12 months, valsartan was associated with a decrease in CRP in patients not receiving ACE inhibitors but not in those receiving ACE inhibitors at 12 months.	Valsartan	91-100	C-reactive protein	Homo sapiens	135-138	
15172423-13	2004	Valsartan but not amlodipine reduced CRP levels.	Valsartan	0-9	C-reactive protein	Homo sapiens	37-40	
15172423-15	2004	CONCLUSIONS: The ARB valsartan has BP-independent effects on LVH, ROS formation by monocytes, and CRP in hypertensive patients with LVH.	Valsartan	21-30	C-reactive protein	Homo sapiens	98-101